2019
Baseline Characteristics of the VANISH Cohort
Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY. Baseline Characteristics of the VANISH Cohort. Circulation Heart Failure 2019, 12: e006231. PMID: 31813281, PMCID: PMC7219518, DOI: 10.1161/circheartfailure.119.006231.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAngiotensin II Type 1 Receptor BlockersBrazilCanadaCardiomyopathy, HypertrophicChildDenmarkDisease ProgressionDouble-Blind MethodFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationPhenotypeRecovery of FunctionSarcomeresTime FactorsTreatment OutcomeUnited StatesValsartanYoung AdultConceptsAngiotensin receptor blockersHypertrophic cardiomyopathyReceptor blockersBaseline characteristicsImaging abnormalitiesPrimary cohortMutation carriersNew York Heart Association class IINew York Heart Association classFunctional class II symptomsOlder ageClass II symptomsNonobstructive hypertrophic cardiomyopathyNormal functional capacityPrevious trialsVentricular wall thicknessPeak oxygen consumptionPlacebo-controlled designCardiac magnetic resonanceGene mutation carriersLate gadolinium enhancementVANISH trialAdvanced diseaseAssociation classVentricular hypertrophy
2018
Text Messaging in Oncology: A Review of the Landscape
Mougalian SS, Gross CP, Hall EK. Text Messaging in Oncology: A Review of the Landscape. JCO Clinical Cancer Informatics 2018, 2: 1-9. PMID: 30652579, DOI: 10.1200/cci.17.00162.Peer-Reviewed Original Research